Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.64 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784513 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BMEN1ELANEKMT2A | |
| SCHEMBL6785920 | 0.82 | MTNR1A (0.70) | MTNR1AMTNR1BNPC1RAB9AFAAH | |
| SCHEMBL6790908 | 0.82 | MTNR1A (0.69) | MTNR1AMTNR1B | |
| SCHEMBL6784523 | 0.82 | MTNR1A (0.72) | MTNR1AMTNR1B | |
| SCHEMBL6785417 | 0.81 | MTNR1A (0.60) | MTNR1AMTNR1BELANE | |
| SCHEMBL6784569 | 0.78 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6786689 | 0.77 | MTNR1B (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6783528 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL6784446 | 0.76 | MTNR1A (0.81) | MTNR1AMTNR1B | |
| SCHEMBL6786579 | 0.75 | MTNR1A (0.86) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737431-B2 | SUCH AS N-(3-(2-METHYLBENZOXAZOL-7-YL)PROPYL)PROPANAMIDE; CIRCADIAN RHYTHM RELATED DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-18 | — | — | US | disclosed |
| US-20030216456-A1 | Benzoxazole derivatives as novel melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216456-A1 | Benzoxazole derivatives as novel melatonergic agents | MTNR1A, MTNR1B, MC1R | MTNR1A 1/4885MTNR1B 2/4885NPC1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.